

# New Products - Jakavi

---

Jakavi (**ruxolitinib phosphate**) is an inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 with nanomolar potency. JAKs mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function. Ruxolitinib inhibits JAK-STAT signalling and cell proliferation of cytokine dependent cellular models of haematological malignancies. Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Jakavi is available as 5 mg, 15 mg and 20 mg tablets in packs of 56's.

*This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.*